JP2024119791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024119791A5 JP2024119791A5 JP2024070972A JP2024070972A JP2024119791A5 JP 2024119791 A5 JP2024119791 A5 JP 2024119791A5 JP 2024070972 A JP2024070972 A JP 2024070972A JP 2024070972 A JP2024070972 A JP 2024070972A JP 2024119791 A5 JP2024119791 A5 JP 2024119791A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- hvr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001413 amino acids Chemical group 0.000 claims 149
- 239000000556 agonist Substances 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 4
- 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 claims 4
- 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 229960004641 rituximab Drugs 0.000 claims 3
- 108010087819 Fc receptors Proteins 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 229960002450 ofatumumab Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001010591 Homo sapiens Interleukin-20 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100030692 Interleukin-20 Human genes 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 108010067003 Interleukin-33 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108090000630 Oncostatin M Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 238000002679 ablation Methods 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 108091006374 cAMP receptor proteins Proteins 0.000 claims 1
- 238000000315 cryotherapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940080856 gleevec Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 108091008042 inhibitory receptors Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000007674 radiofrequency ablation Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662304018P | 2016-03-04 | 2016-03-04 | |
| US62/304,018 | 2016-03-04 | ||
| PCT/US2017/020745 WO2017152102A2 (en) | 2016-03-04 | 2017-03-03 | Anti-trem1 antibodies and methods of use thereof |
| JP2018546004A JP7023853B2 (ja) | 2016-03-04 | 2017-03-03 | 抗ｔｒｅｍ１抗体及びその使用方法 |
| JP2022018475A JP7480197B2 (ja) | 2016-03-04 | 2022-02-09 | 抗ｔｒｅｍ１抗体及びその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022018475A Division JP7480197B2 (ja) | 2016-03-04 | 2022-02-09 | 抗ｔｒｅｍ１抗体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024119791A JP2024119791A (ja) | 2024-09-03 |
| JP2024119791A5 true JP2024119791A5 (enExample) | 2025-01-20 |
Family
ID=58348000
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546004A Active JP7023853B2 (ja) | 2016-03-04 | 2017-03-03 | 抗ｔｒｅｍ１抗体及びその使用方法 |
| JP2022018475A Active JP7480197B2 (ja) | 2016-03-04 | 2022-02-09 | 抗ｔｒｅｍ１抗体及びその使用方法 |
| JP2024070972A Withdrawn JP2024119791A (ja) | 2016-03-04 | 2024-04-24 | 抗ｔｒｅｍ１抗体及びその使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546004A Active JP7023853B2 (ja) | 2016-03-04 | 2017-03-03 | 抗ｔｒｅｍ１抗体及びその使用方法 |
| JP2022018475A Active JP7480197B2 (ja) | 2016-03-04 | 2022-02-09 | 抗ｔｒｅｍ１抗体及びその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US11472877B2 (enExample) |
| EP (1) | EP3423493A2 (enExample) |
| JP (3) | JP7023853B2 (enExample) |
| WO (1) | WO2017152102A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| JP7267280B2 (ja) * | 2017-08-08 | 2023-05-01 | パイオニア イミュノセラピューティクス インコーポレイテッド | Ｔｒｅｍ１を発現する骨髄細胞を無能化させるための組成物および方法 |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| EP4603508A3 (en) | 2017-12-19 | 2025-10-29 | Surrozen Operating, Inc. | Anti-frizzled antibodies and methods of use |
| WO2019125981A1 (en) | 2017-12-19 | 2019-06-27 | Musc Foundation Of Research Development | T regulatory (trey) cell translantation in osteogenesis imperfecta (oi) |
| US11773171B2 (en) | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
| CN111886246B (zh) * | 2017-12-29 | 2024-12-17 | 艾莱克特有限责任公司 | 抗tmem106b抗体及其使用方法 |
| KR102495666B1 (ko) | 2018-03-14 | 2023-02-06 | 서피스 온콜로지, 인크. | Cd39에 결합하는 항체 및 이의 용도 |
| EA202092302A1 (ru) | 2018-04-02 | 2021-02-02 | Бристол-Майерс Сквибб Компани | Антитела к trem-1 и их применения |
| AU2019344524A1 (en) | 2018-09-17 | 2021-03-25 | The Brigham And Women’S Hospital, Inc. | Anti-KLRG1 antibodies |
| EP3875484A4 (en) * | 2018-10-26 | 2022-07-20 | CRAGE medical Co., Limited | Cll1-targeting antibody and application thereof |
| KR20210126638A (ko) * | 2019-02-06 | 2021-10-20 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem1 항체 및 관련 방법 |
| US10836828B2 (en) | 2019-02-06 | 2020-11-17 | Pionyr Immunotherapeutics, Inc. | Anti-TREM1 antibodies and related methods |
| CN110170053A (zh) * | 2019-05-30 | 2019-08-27 | 澳门科技大学 | 组合物、其在制备肿瘤免疫治疗药物中的应用及药物组合物 |
| US20220372139A1 (en) | 2019-07-15 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| US20220332817A1 (en) | 2019-07-15 | 2022-10-20 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
| MX2022003005A (es) | 2019-09-16 | 2022-04-07 | Surface Oncology Inc | Composiciones y metodos de anticuerpos anti-cd39. |
| PE20231082A1 (es) * | 2020-06-26 | 2023-07-17 | Amgen Inc | Muteinas de il-10 y proteinas de fusion de las mismas referencia cruzada a solicitudes relacionadas |
| JP2023550596A (ja) * | 2020-11-02 | 2023-12-04 | ユーシービー バイオファルマ エスアールエル | 運動ニューロン神経変性障害の治療のための抗ｔｒｅｍ１中和抗体の使用 |
| CA3218933A1 (en) | 2021-05-03 | 2022-11-10 | UCB Biopharma SRL | Antibodies |
| AU2022287235A1 (en) * | 2021-06-02 | 2023-12-14 | Inotrem | Anti-trem-1 antibodies |
| CA3224001A1 (en) * | 2021-06-25 | 2022-12-29 | Amgen Inc. | Treatment of cardiovascular disease with trem-1 antigen binding proteins |
| WO2024220958A1 (en) | 2023-04-21 | 2024-10-24 | Celsius Therapeutics, Inc. | Anti-trem1 antibody agents, compositions, and uses thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1222292B1 (en) | 1999-10-04 | 2005-08-31 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| US20080181888A1 (en) | 2004-12-31 | 2008-07-31 | Ambrose Christine M | Polypeptides That Bind Br3 and Uses Thereof |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| WO2007106585A1 (en) | 2006-03-15 | 2007-09-20 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| CN101855242B (zh) | 2007-09-14 | 2014-07-30 | 阿迪马布有限责任公司 | 合理设计的合成抗体文库及其用途 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2010132370A2 (en) | 2009-05-11 | 2010-11-18 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Soluble tlt-1 for the treatment and diagnosis of sepsis |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| WO2011047097A2 (en) | 2009-10-13 | 2011-04-21 | Sigalov Alexander B | Inhibition of trem receptor signaling with peptide variants |
| EP3336225B1 (en) | 2010-07-16 | 2020-02-19 | Adimab, LLC | Antibody libraries |
| HRP20171585T1 (hr) * | 2012-02-15 | 2017-12-01 | Novo Nordisk A/S | Antitijela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloičnim stanicama 1 (trem-1) |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| HRP20200875T8 (hr) | 2012-09-07 | 2021-04-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitorni peptidi porijeklom od aktivirajućeg receptora eksprimiranog na mijeloidnim stanicama-1 (trem-1)-sličnog transkripta 1 (tlt-1) i nihove upotrebe |
| AP2015008584A0 (en) * | 2013-02-08 | 2015-07-31 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
| SI3172232T1 (sl) | 2014-07-17 | 2024-05-31 | Novo Nordisk A/S | Na mesto usmerjena mutageneza protiteles TREM-1 za zmanjšanje viskoznosti |
| CN110662765B (zh) * | 2017-08-03 | 2023-09-29 | 艾利妥 | 抗cd33抗体及其使用方法 |
-
2017
- 2017-03-03 US US16/078,965 patent/US11472877B2/en active Active
- 2017-03-03 WO PCT/US2017/020745 patent/WO2017152102A2/en not_active Ceased
- 2017-03-03 JP JP2018546004A patent/JP7023853B2/ja active Active
- 2017-03-03 EP EP17711511.0A patent/EP3423493A2/en active Pending
-
2022
- 2022-02-09 JP JP2022018475A patent/JP7480197B2/ja active Active
- 2022-09-13 US US17/931,757 patent/US12110327B2/en active Active
-
2024
- 2024-04-24 JP JP2024070972A patent/JP2024119791A/ja not_active Withdrawn
- 2024-09-04 US US18/824,619 patent/US20250092131A1/en active Pending